Key result
HF and pulmonary hypertension frequently complicate myeloproliferative neoplasms in a bidirectional relationship.
Answers are grounded in this paper and cite their sources.
This review highlights the importance of recognizing and managing nonthrombotic cardiovascular complications, specifically heart failure and pulmonary hypertension, in patients with myeloproliferative neoplasms.
Patients with myeloproliferative neoplasms (MPNs) are at increased risk for cardiovascular disease. Although thrombosis is a well-recognized complication, emerging evidence indicates that nonthrombotic conditions, including heart failure (HF) and pulmonary hypertension (PH), are also prevalent and associated with adverse cardiovascular and hematologic outcomes. Clinical and preclinical data suggest a shared pathophysiology linking MPNs to the development and progression of cardiomyopathy, HF, and both precapillary and postcapillary PH. Recent studies further support a bidirectional relationship, in which HF and PH are associated with hematologic progression and vice versa. Elucidating the mechanisms underlying these interactions may uncover novel therapeutic targets and inform clinical management. Here, the authors review the pathophysiology and impact of HF and PH in patients with MPNs.
No takes yet. Share an insight, caveat, or question.
Leiva et al. (2025) conducted a review in Myeloproliferative neoplasms. Heart failure and pulmonary hypertension was evaluated. Heart failure and pulmonary hypertension are prevalent nonthrombotic complications in patients with myeloproliferative neoplasms, sharing a bidirectional relationship with hematologic progression.
Synapse has enriched 10 related papers. Consider them for comparative context: